Clinical trials of several HDAC inhibitors including valproic acid, vorinostat, romidepsin, belinostat and panabinostat have been conducted in both solid tumours and haematological malignancies including AML, MDS and CMML patients [18–22]. This evidence concerns the gene HDAC9 and chronic myelomonocytic leukemia.